Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

• US 5,208,249 A
• Filed: 08/20/1992
• Issued: 05/04/1993
• Est. Priority Date: 08/20/1992
• Status: Expired due to Fees

• Current Assignee: Xanthus Life Sciences, Inc. (Sarossa Plc)
• Original Assignee: Clintec Nutrition Company
• Inventors: Goldberg, Dennis I., Rowe, W. Bruce
• Primary Examiner(s): Cintins, Marianne M.
• Assistant Examiner(s): Hydorn, Michael B.
• Application Number:
  US07/932,761
• Time in Patent Office: 257 Days
• Field of Search: 514/369
• US Class Current: 514/369
• CPC Class Codes: A61K 31/425 Thiazoles
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method for stimulating the intracellular synthesis of glutathione comprising the step of administering to a mammal a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate is provided.

Claims

1. A method for stimulating the intracellular synthesis of glutathione comprising the step of administering to a mammal a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate for stimulating the intracellular synthesis of glutathione.

2. The method of claim 1 wherein the ester is chosen from the group consisting of alkyls having 1 to 10 carbon atoms.

3. The method of claim 1 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered parenterally.

4. The method of claim 1 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered enterally.

5. The method of claim 1 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered topically.

6. The method of claim 1 wherein the ester is ethyl.

7. A method for stimulating the intracellular synthesis of glutathione in cells not readily penetratable by L-2-oxothiazolidine-4-carboxylate comprising the step of administering to a patient a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate in an amount sufficient to stimulate the intracellular synthesis of cells that are not readily penetrated by 2-oxothiazolidine-4-carboxylate.

8. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered to stimulate the intracellular synthesis of glutathione in the brain cells of a patient.

9. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered to stimulate the intracellular synthesis of glutathione in at least select cells of the skin of a patient.

10. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered to stimulate the intracellular synthesis of glutathione in cells located in the spinal cord of a patient.

11. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered to stimulate the intracellular synthesis of glutathione in cells of the peripheral nervous system of a patient.

12. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered to stimulate the intracellular synthesis of glutathione in cells of the cornea of a patient.

13. The method of claim 7 wherein the ester is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tertiary butyl esters.

14. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered enterally.

15. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered parenterally.

16. The method of claim 7 wherein the ester of 2-oxothiazolidine-4-carboxylate is administered topically.

17. A topical ointment capable of stimulating the intracellular synthesis of glutathione in at least cells to which the ointment is applied comprising:

a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate that is an oil at room temperature; and

a mineral oil base.

18. The topical ointment of claim 17 wherein the ester is ethyl.

19. An ophthalmic ointment capable of stimulating the intracellular synthesis of glutathione in the cells of a patient'"'"'s eye comprising:

a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate that is an oil at room temperature; and

a base chosen from the group consisting of non-irritant oils and lipids.

20. The ophthalmic ointment of claim 19 wherein the base includes mineral oil.